Athersys and Chugai partner on stem cell therapy for stroke
Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.
Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.
People who work irregular hours get sick more often because proteins that set the human body clock are also involved in DNA repair say US researchers who think drugs targeting the molecules could be used to treat cancer.
A district court judge from California has denied an injunction by Amgen meant to stop the launch of the first biosimilar approved by the US FDA – Sandoz’s Zarxio (filgrastim-sndz).
Nanobodies may be more effective at treating the norovirus than mAbs.